None listed
Conditions
Interventions
IVERMECTIN Type of group
The participants will receive one (1) daily dose of 300 mcg/kg ivermectina for three (3) consecutive days. The Ivermectin presentation will be an oral drop solution.
Group name:Ivermectin placebo Type of group
The participants will receive one (1) daily dose of an ivermectin placebo for three (3) consecutive days. The placebo presentation will be an oral drop solution undistinguishable
Sponsors
UNIVERSIDAD PERUANA CAYETANO HEREDIA,
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with COVID-19 typical symptoms (cough, fever, anosmia) present for not more than 96 hours, 2. The patient must be elder than 18 years old. 3. Not previous administration of ivermectin before the study. 4. No known history of ivermectin allergy. 5. The patient can give his consent to take part in the study. 6. Current use of CYP 3A4 or P-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. Use of critical CYP3A4 substrate drugs such as warfarin.
Exclusion criteria
Exclusion criteria: 1. COVID-19 pneumonia • Diagnosed by the attending physician (oxygen saturation < 95% or lung crackles) 2. Positive pregnancy test for women of child bearing age 3. Positive IgG against SARS-CoV-2 by rapid diagnostic test. 4. Negative SARS-CoV-2 PCR from a nasopharyngeal swab.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:Use of PCR for SARS-CoV-2. The primary outcome measure will be assessed using Fisher´s exact test. Measure:Proportion of patients with a positive SARS-CoV-2 PCR from a nasopharyngeal swab at day 7 post-treatment Timepoints:At day 7 post-treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:The study will use the burden and proportion of intestinal parasites. Measure:Instestinal parasites by means of cuatitative kato-kats and Baerman. Timepoints:At day 1 and 14 ; Outcome name:The mean viral load as determined by PCR clycle threshold (Ct) will be used. Measure:Viral load as determined by PCR cycle threshold (Ct). Timepoints:At baseline and on days 4, 7, 14, and 21 ; Outcome name:The proportion of patients with fever an cough will be used. Measure:Patients with fever and cough Timepoints:At days 4, 7, 14 and 21 post-treatment ; Outcome name:The proportion of patients with seroconversion will be used Measure:Patients with seroconversion Timepoints:At day 21 ; Outcome name:The study will use the proportion of drugrelated adverse events. Measure:Drug-related adverse events Timepoints:During the entire study | — |
Countries
Peru
Contacts
Public ContactPatricia Jannet Garcia
UNIVERSIDAD PERUANA CAYETANO HEREDIA
Outcome results
None listed